hase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICA

Re: Rana R. McKay, Karla V. Ballman, Pamela J. Atherton, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026;44:2341–52 / Roviello, G., Antonuzzo, L.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - ELETTRONICO. - (2026), pp. 1-2. [10.1016/j.eururo.2026.08.016]

Re: Rana R. McKay, Karla V. Ballman, Pamela J. Atherton, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026;44:2341–52

Roviello, Giandomenico;Antonuzzo, Lorenzo
2026

Abstract

hase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICA
2026
1
2
Roviello, Giandomenico; Antonuzzo, Lorenzo
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S030228382602364X-main.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 275.68 kB
Formato Adobe PDF
275.68 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1499891
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact